Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Current Assets (2021 - 2025)

Historic Current Assets for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $925.6 million.

  • Krystal Biotech's Current Assets rose 2979.48% to $925.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $925.6 million, marking a year-over-year increase of 2979.48%. This contributed to the annual value of $742.0 million for FY2024, which is 2621.77% up from last year.
  • Krystal Biotech's Current Assets amounted to $925.6 million in Q3 2025, which was up 2979.48% from $841.3 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Current Assets peaked at $925.6 million during Q3 2025, and registered a low of $345.8 million during Q3 2021.
  • Moreover, its 5-year median value for Current Assets was $484.0 million (2023), whereas its average is $552.4 million.
  • Its Current Assets has fluctuated over the past 5 years, first tumbled by 1885.15% in 2023, then surged by 6944.26% in 2024.
  • Quarter analysis of 5 years shows Krystal Biotech's Current Assets stood at $442.3 million in 2021, then fell by 13.22% to $383.8 million in 2022, then skyrocketed by 53.19% to $587.9 million in 2023, then grew by 26.22% to $742.0 million in 2024, then increased by 24.74% to $925.6 million in 2025.
  • Its Current Assets stands at $925.6 million for Q3 2025, versus $841.3 million for Q2 2025 and $766.8 million for Q1 2025.